Investing
Pfizer inks $43 billion Seagen deal to boost cancer portfolio
© Reuters. FILE PHOTO: The Pfizer logo is pictured on their headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. REUTERS/Carlo Allegri
(Reuters) – Pfizer Inc (NYSE:) on Monday struck a roughly $43 billion deal for Seagen Inc to bulk up its cancer treatment portfolio, as the drugmaker braces for a steep fall in COVID-19 product sales and loss of exclusivity for some top sellers.
The deal, Pfizer’s largest since its $67 billion acquisition of Wyeth in 2009, will add four approved cancer therapies with combined sales of nearly $2 billion in 2022.
Analysts expect that sales to double by 2025, according to Refinitiv data.
Pfizer has offered $229 in cash per Seagen share, a 32.7% premium to Friday’s closing price.
Shares of Seagen were up 23% before the bell.
Read the full article here
-
Side Hustles6 days ago
Protect Your Business With AdGuard VPN’s Powerful Security Features
-
Passive Income6 days ago
This Minimalist Lamp Lets You Pick From 16 Million+ Lighting Colors for Maximum Productivity
-
Make Money5 days ago
15 Jobs That Will Shrink the Fastest Over the Next Decade
-
Side Hustles4 days ago
3 Steps You Can’t Miss When Growing Your Business
-
Side Hustles5 days ago
How to Maximize Your Profits With This Annual 8-Step Checklist
-
Side Hustles5 days ago
Want to Start a Business? Consider Buying One Instead — Here’s Why.
-
Passive Income5 days ago
Why Email Marketing Is Still Your Business’s Most Powerful Tool
-
Investing5 days ago
Netherlands stocks lower at close of trade; AEX down 0.80% By Investing.com